[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625557":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":36,"locations":46,"responsibleParty":60,"collaborators":64,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":27,"eligibilityCriteria":73,"healthyVolunteers":70,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":27,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":90,"whyStopped":27,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of Pennsylvania","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"LT4+LT3","EXPERIMENTAL","Levothyroxine plus liothyronine therapy",[13,14],"Drug: Liothyronine (L-T3)","Drug: Levothyroxine Sodium (LT4) Tablets",{"label":16,"type":17,"description":18,"interventionNames":19},"LT4+placebo","ACTIVE_COMPARATOR","Levothyroxine plus liothyronine placebo",[14,20],"Drug: Liothyronine (LT3) placebo",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Liothyronine (L-T3)","Participants will either take LT3 with an LT4 dose that is reduced from baseline or they will take liothyronine placebo with their baseline LT4 dose.",[9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Levothyroxine Sodium (LT4) Tablets","All participants will take levothyroxine.",[9,16],{"type":23,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"Liothyronine (LT3) placebo","Identical placebo tablet without containing liothyronine",[16],[37,42],{"name":38,"role":39,"phone":40,"phoneExt":27,"email":41},"Anne R. Cappola, MD, ScM","CONTACT","215-573-5359","acappola@pennmedicine.upenn.edu",{"name":43,"role":39,"phone":44,"phoneExt":27,"email":45},"Theresa Scattergood, MSN, RN","215-898-5664","theresa.scattergood@pennmedicine.upenn.edu",[47],{"facility":48,"status":27,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":27},"Penn Medicine, Smilow Center for Translational Resarch,","Philadelphia","Pennsylvania","19104","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-75.16362,39.95238,{"lat":58,"lon":57},{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"PRINCIPAL_INVESTIGATOR","Anne Cappola, MD","Professor of Medicine",[65],{"name":66,"class":67},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100625557","phase-2-t4t3-therapy-in-hypothyroidism-100625557",false,"NCT07424183","T4\u002FT3 Therapy in Hypothyroidism","Inclusion Criteria:\n\n1. Male or female, aged 18-70 years\n2. Hypothyroidism due to either thyroid failure or total thyroidectomy for structural thyroid disease (nodules, benign goiter, or thyroid cancer) for at least 6 months\n3. Taking 75-150 mcg per day LT4 and a minimum of 1.2 mcg\u002Fkg\u002Fday, with stable dose of LT4 for at least 3 months prior to enrollment\n4. TSH of 0.5 to 4.0 mU\u002FL within 2 months of enrollment\n5. Persistent symptoms for at least 2 months, and a TSQ score of ≥ 5\n6. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of study intervention.\n\nExclusion Criteria:\n\n1. Current use of LT3, thyroid extracts, Tirosint liquid or capsules, amiodarone, lithium, methimazole, propylthiouracil, supraphysiologic doses of corticosteroids, immunotherapy, tyrosine kinase inhibitors, interferon, or biotin supplements\n2. Diseases of the pituitary or hypothalamus\n3. History of thyroid cancer requiring suppression of TSH secretion\n4. Unstable cardiac conditions, including uncontrolled hypertension (current blood pressure greater than 160\u002F100), arrhythmia, or angina\n5. Uncontrolled psychiatric disorders\n6. Pregnancy or lactation, or planned pregnancy within the next 7 months\n7. History of food dye allergies\n8. GFR \\\u003C30 ml\u002Fmin\u002F1.73 m2\n9. Other conditions which, in the opinion of the investigators, would prevent them from participating in the full duration of the study (for example, end-stage cancer)","ALL","18 Years","70 Years",{"count":78,"type":79},60,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","This study will test whether 6 months of combination therapy with levothyroxine (LT4) plus liothyronine (LT3) is superior to LT4 plus placebo in participants with hypothyroidism who have residual symptoms of hypothyroidism with TSH levels within the reference range.",[85],"Hypothyroidism Primary",[87,88,89],"Hypothyroidism","levothyroxine","liothyronine","NOT_YET_RECRUITING","2026-04-16",{"date":93,"type":94},"2026-04-21","ACTUAL",{"date":96,"type":79},"2026-06",{"date":98,"type":79},"2027-06",{"name":5,"class":6},1]